Classifying new anti-tuberculosis drugs: rationale and future perspectives
نویسندگان
چکیده
منابع مشابه
Classifying new anti-tuberculosis drugs: rationale and future perspectives.
The classification of anti-tuberculosis (TB) drugs is important as it helps the clinician to build an appropriate anti-TB regimen for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases that do not fulfil the criteria for the shorter MDR-TB regimen. The World Health Organization (WHO) has recently approved a revision of the classification of new anti-TB drugs based on curren...
متن کاملNew drugs and perspectives for new anti-tuberculosis regimens.
Tuberculosis (TB) is the ninth cause of global death, more than any other infectious disease. With growing drug resistance the epidemic remains and will require significant attention and investment for the elimination of this disease to occur. With susceptible TB treatment not changing over the last four decades and the advent of drug resistance, new drugs and regimens are required. Recently, t...
متن کاملAMD Future Perspectives: New promising drugs Authors:
Introduction As researchers and clinicians begin to understand that wet age-related macular degeneration (wAMD) is a complex disease with angiogenic, vascular and inflammatory components, new pharmacological agents addressing multiple targets in its pathophysiology keep being introduced. While some drugs are already available in human trials or even FDA and EMA-approved, most are still under la...
متن کاملNew anti-tuberculosis agents amongst known drugs.
Mycobacterium tuberculosis has an on-going impact on global public health and new therapeutics to treat tuberculosis are urgently required. The emergence of drug resistant tuberculosis poses a serious threat to the control of this pathogen, and the development of drugs that are active against the resistant strains is vital. A medium-throughput assay using the Alamar Blue reagent was set-up to i...
متن کاملNew drugs for tuberculosis: current status and future prospects.
This article reviews two classes of compounds that have advanced into phase II and III clinical trials, long-acting rifamycins and fluoroquinolones, and a number of other drugs that have entered or may enter clinical development in the near future.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Infectious Diseases
سال: 2017
ISSN: 1201-9712
DOI: 10.1016/j.ijid.2016.10.026